Wire · opportunities
BMS Uses NVIDIA AI to Accelerate Drug Discovery
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
Bristol Myers Squibb has deployed NVIDIA's latest DGX SuperPOD infrastructure to create what it claims is the life sciences industry's most powerful privately owned AI system, delivering 10x greater performance per megawatt than its predecessor. The expanded compute capacity supports BMS's 'Predict First' drug discovery approach and a strategic partnership with Anthropic to deploy Claude agents across research, development, and manufacturing workflows.
This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
BMS has just bought compute that lets its AI agents run drug discovery at scale that human chemists cannot match. If you sell target identification, synthesis optimization, or lab automation into pharma, your customer's internal AI now does some of your job - and you need to become the layer BMS cannot build in-house.
◆ Related on Wire
◆ Topics